1396 Prednisolone for Bell’s Palsy in children: A randomised, double-blind, placebo-controlled, Multicentre Trial
نویسندگان
چکیده
Aims, Objectives and Background Corticosteroids can be used to treat idiopathic facial paralysis (Bell’s palsy) in children, but their effectiveness is uncertain. Aims To determine if prednisolone improves recovery of children with Bell’s palsy at one month. Method Design Double-blind, placebo-controlled, randomised, trial presenting ED palsy. 1 Patients 6 months <18 years, recruited <72 hours after symptom onset, were randomly assigned receive 10 days treatment oral (1 mg/kg) or placebo. The primary outcome: complete function month on the House-Brackmann scale. 2 Secondary outcomes: function, adverse events pain months. Results Conclusion Between October 2015 August 2020, 187 randomised (94 93 placebo) included intention-to-treat analysis. At month, proportions patients who had recovered 49% (n=43/87) group compared 57% (n=50/87) placebo (risk difference -8.1%, 95% CI -22.8 6.7; adjusted odds ratio [aOR] 0.7, 0.4 1.3). these proportion 99% (n=77/78) for 93% (n=76/82) respectively 6.0%, -0.1 12.2; aOR 3.0 0.5 17.7) (figure 1). There no serious little evidence differences secondary outcomes. Abstract 1396 Figure In vast majority recover without treatment. study does not provide that early recovery. References Sullivan F, Swan I, Donna P, Morrison J, Smith B, McKinstry et al . Early acyclovir bell’s N Eng J Med 2007; 357 (16):1598–607. House JW, Brackmann DE. Facial nerve grading system. Otolaryngol Head Neck Surg 1985; (2):146–7.
منابع مشابه
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial
BACKGROUND Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination a...
متن کامل5-HT3 antagonist for cognition improvement in schizophrenia: a double blind, placebo-controlled trial
Introduction: Patients with schizophrenia characteristically exhibit cognitive deficits. The level of cognitive impairment is found to predict the functional outcome of the illness more strongly than the severity of positive or negative symptoms. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic...
متن کاملProphylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND Ibuprofen is used for treatment and prevention of patent ductus arteriosus in low-birthweight infants. Its effects on regional circulations differ from those of indometacin. Because prophylactic indometacin reduces the frequency of severe intraventricular haemorrhage and patent ductus arteriosus, we aimed to study the efficacy of early ibuprofen in reducing these outcomes in a double...
متن کاملMemantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND Memantine has been used off-label to treat frontotemporal lobar degeneration (FTD). A previous 26-week open-label study suggested a transient, modest benefit on neuropsychiatric symptoms as measured by the neuropsychiatric inventory (NPI). We aimed to determine whether memantine is an effective treatment for FTD. METHODS We did a randomised, parallel group, double-blind, placebo-co...
متن کاملAdjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND Adjuvant endocrine therapy compromises bone health in patients with breast cancer, causing osteopenia, osteoporosis, and fractures. Antiresorptive treatments such as bisphosphonates prevent and counteract these side-effects. In this trial, we aimed to investigate the effects of the anti-RANK ligand antibody denosumab in postmenopausal, aromatase inhibitor-treated patients with early-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Emergency Medicine Journal
سال: 2022
ISSN: ['1472-0205', '1472-0213']
DOI: https://doi.org/10.1136/emermed-2022-rcem2.9